EP3853230 - CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 25.06.2021 Database last updated on 19.10.2024 | |
Former | The international publication has been made Status updated on 28.03.2020 | Most recent event Tooltip | 17.08.2024 | New entry: Application deemed to be withdrawn: despatch of communication + time limit | Applicant(s) | For all designated states Vyera Pharmaceuticals, LLC 600 Third Avenue, 10th Floor New York, NY 10016 / US | For all designated states Washington University One Brookings Drive St. Louis, Missouri 63130 / US | [2021/30] | Inventor(s) | 01 /
HOPPER, Allen T. 75 Adams Street Lexington, MA 02420 / US | 02 /
SIBLEY, L. David 7333 Teasdale Avenue University City, MO 63130 / US | 03 /
JANETKA, James W. 7470 Teasdale Drive St. Louis, MO 63130 / US | [2021/30] | Representative(s) | (deleted) | [N/P] |
Former [2021/30] | HGF 1 City Walk Leeds LS11 9DX / GB | Application number, filing date | 19863891.8 | 19.09.2019 | [2021/30] | WO2019US51877 | Priority number, date | US201862733361P | 19.09.2018 Original published format: US 201862733361 P | [2021/30] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020061279 | Date: | 26.03.2020 | Language: | EN | [2020/13] | Type: | A1 Application with search report | No.: | EP3853230 | Date: | 28.07.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.03.2020 takes the place of the publication of the European patent application. | [2021/30] | Search report(s) | International search report - published on: | IL | 26.03.2020 | (Supplementary) European search report - dispatched on: | EP | 03.06.2022 | Classification | IPC: | C07D487/04, A61K31/519, A61P33/02, A61P33/06 | [2021/30] | CPC: |
C07D487/04 (EP,US);
A61P33/02 (EP);
A61P33/06 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/30] | Extension states | BA | 13.04.2021 | ME | 13.04.2021 | Validation states | KH | 13.04.2021 | MA | 13.04.2021 | MD | 13.04.2021 | TN | 13.04.2021 | Title | German: | CDPK1-INHIBITOREN, ZUSAMMENSETZUNGEN UND VERFAHREN IM ZUSAMMENHANG DAMIT | [2021/30] | English: | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | [2021/30] | French: | INHIBITEURS DE CDPK1, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS | [2021/30] | Entry into regional phase | 13.04.2021 | National basic fee paid | 13.04.2021 | Search fee paid | 13.04.2021 | Designation fee(s) paid | 13.04.2021 | Examination fee paid | Examination procedure | 13.04.2021 | Examination requested [2021/30] | 29.12.2022 | Amendment by applicant (claims and/or description) | 16.08.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | Fees paid | Renewal fee | 30.11.2021 | Renewal fee patent year 03 | 16.08.2022 | Renewal fee patent year 04 | 26.09.2023 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 30.09.2021 | 03   M06   Fee paid on   30.11.2021 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [ ] - No further relevant documents disclosed | International search | [X]WO2009062118 (FOLDRX PHARMACEUTICALS INC [US], et al) [X] 1-10, 12, 13, 16-21, 25-27, 35, 37, 39-41, 69, 70, 75 * Compounds 11, 19-22, 48, 50-52, 56, 58-60, 64, 65, 68, 90, 128, 133, 134, 137, 140, 142-147, 150, 165-169, 174-180, 183-185, 193-197, 200, 201, 205, 206, 220, 221, 256, 260, 278, 331, 341, 357-359, 362, 370, 380, 381, 386, 414, 417, 420, 429-432, 437, 438, 440, 441, 447-450, 454 and 463. *; | [X]US2012077827 (IBRAHIM PRABHA N [US], et al) [X] 1-3, 5-10, 12, 13, 16, 37, 39-41, 69, 70, 75 * Compounds la-lc, 2a-2d, 4a-4d and paragraph [0090]. *; | [X]WO2017161344 (THE REGANTS OF THE UNIV OF CALIFORNIA [US], et al) [X] 1-79 * The whole document. *; | [XP]WO2018170236 (VYERA PHARMACEUTICALS LLC [US]) [XP] 1-16, 33-45, 57, 58, 61-79 * The whole document. *; | [XP]WO2019036001 (VYERA PHARMACEUTICALS LLC [US], et al) [XP] 1-16, 33-45, 57, 58, 61-79* The whole document. *; | [X] - RUTAGANIRA, F. U. et al., "Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii", Journal of medicinal chemistry, vol. 60, no. 24, doi:10.1021/acs.jmedchem.7b01192, (20170921), pages 9976 - 9989, URL: https://europepmc.org/article/PMC/5746462, XP055571647 [X] 1-3, 5-10, 12, 13, 19-21, 23, 25-30, 35, 39, 40, 63-79 * Figures 1-3. * DOI: http://dx.doi.org/10.1021/acs.jmedchem.7b01192 | [X] - LOURIDO S. et al., "Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii", Journal of medicinal chemistry, vol. 56, no. 7, doi:10.1021/jm4001314, (20130326), pages 3068 - 3077, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625458, XP055479238 [X] 1, 2, 5-10, 12, 13, 19-21, 35, 39, 40, 63-79 * Figure 1 and Table 1. * DOI: http://dx.doi.org/10.1021/jm4001314 | [XY] - KUHLENSCHMIDT, T. B. et al., "Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture", Antimicrob Agents Chemother, (20151109), vol. 60, no. 1, pages 570 - 579, XP055695132 [X] 1, 2, 4-8, 10, 12, 13, 19-21, 39, 40, 63-79 * Figure 1, compounds 9-20. Figure 1, compound 5. * [Y] 16, 36-38, 45, 61 DOI: http://dx.doi.org/10.1128/AAC.01915-15 |